TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical indication for cardioversion of AF~* Current episode of symptomatic AF lasting between 3-hour and 7 days (inclusive) at randomization~* Adequate anticoagulation according to international and/or national guidelines~Key Exclusion Criteria:~* Significant clinical illness or surgical procedure within 4 weeks preceding the screening visit~* History of significant mental, renal or hepatic disorder, chronic obstructive pulmonary disease, sinus nodal disease, or other significant disease, as judged by the investigator.~* Any cardioversion attempt of AF or atrial flutter within 4 weeks preceding randomization~* Use of any antiarrhythmic drug class I and/or III within 6 months before randomisation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: AP30663 (Type: EXPERIMENTAL): Participants will receive single dose of AP30663.
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to AP30663.
- Part 2: AP30663 (Type: EXPERIMENTAL): Participants will receive a single dose of one of the multiple dose levels of AP30663.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to AP30663.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females, aged ≥ 18 years (≥ 20 for Japanese subjects) at the time of consent.~2. Have a diagnosis of atopic dermatitis for ≥ 12 months.~3. Have moderate to severe atopic dermatitis which is considered inappropriate for topical therapy or which cannot be adequately controlled by topical therapy.~4. Meet the laboratory criteria as defined per protocol~5. Females of Childbearing Potential (FCBP) must have a negative pregnancy test at Screening and Baseline. Sexually active FCBP must use one of the approved contraceptive options required per protocol while on and for at least 28 days after the last dose of study medication~6. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception while on and for at least 28 days after the last dose of study medication.~Exclusion Criteria:~1. Active tuberculosis (TB) or a history of inadequately treated tuberculosis.~2. Positive for hepatitis B surface antigen or hepatitis C antibody~3. Pregnant or breast feeding~4. History of allergy to any component of the study medication.~5. Active skin infection requiring systemic antimicrobials at Baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 40 mg (Type: EXPERIMENTAL): Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
- Apremilast 30 mg (Type: EXPERIMENTAL): Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
- Placebo + Apremilast 40 mg (Type: EXPERIMENTAL): Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
- Placebo + Apremilast 30 mg (Type: EXPERIMENTAL): Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
- Placebo (Type: PLACEBO_COMPARATOR): Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have chronic hepatitis C infection (genotype 1) with HCV RNA level \>= 1000 IU/mL~* Patient must have failed at least 1 prior course of Peg-IFN/RBV therapy (standard treatment)~* Patient must be willing to use 2 effective methods of birth control for up to 7 months after last dose of study medication~Exclusion Criteria:~* Patient is a previous non-responder that is classified as a viral breakthrough case~* Patient is infected with Hepatitis C virus, genotype 1, exhibiting more than one subtype~* Patient has Hepatitis C virus, genotype 1, and exhibits co-infection with any other genotype~* Evidence of decompensated liver disease~* Patient has condition that requires use of systemic corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A: T12/PR48 (Type: EXPERIMENTAL): Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
- Group B: T12(DS)/PR48 (Type: EXPERIMENTAL): Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
- Group C: Pbo/PR48 (Type: EXPERIMENTAL): Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sugammadex in Renal Diseased Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 65 years old~* end-stage renal disease defined by clearance of creatinine \< 30 ml/min~* normal renal function defined by clearance if creatinine \> 90 ml/min~* candidates to elective surgical procedures (control group) or kidney transplantation (renal group) under general anaesthesia~Exclusion Criteria:~* pregnant and breastfeeding women~* patients with known or suspected neuromuscular disorders~* patients with hepatic disfunction~* a history of malignant hyperthermia~* allergy to narcotics, rocuronium or other medication used during general anaesthesia~* patients receiving medication known to interfere with the action of rocuronium (amino glycoside antibiotics, anticonvulsants, or magnesium)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Renal Group (Type: EXPERIMENTAL): Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
- Control group (Type: ACTIVE_COMPARATOR): Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Liver volume ≥ 4 liter~* ≥ 20 liver cysts~* Symptomatic patients defined as at least 2 out of 5 of the following symptoms related to mass effect irrespective of the intensity:~  * Abdominal distention perceived as uncomfortable~ * Frequent abdominal pain~ * Early satiety~ * Nausea (with the inclusion of dyspeptic complaints)~ * Dyspnea~* Diagnosed with ADPKD or ADPLD~* Male and female patients of 18 years and older~* Written informed consent~Exclusion Criteria:~* Creatinine clearance \< 20 ml/min~* Patient who underwent a kidney transplant and received variable doses of immunosuppressive therapy and/or present signs of rejection in the past year~* Hormonal replacement therapy~* Hormonal contraception~* Pregnant or lactating~* Presenting with an uncontrolled disease (other than ADPKD/ADPLD)~* Planned to undergo any surgery of the liver during study participation~* Planned to undergo any surgery of the KIDNEY during study participation (ADPKD patients only)~* Patients with known allergies to somatostatin or its analogues or any of its components~* Patients who received somatostatin analogues in the 6 months preceding study inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symptomatic polycystic liver disease (PCLD) patients (Type: EXPERIMENTAL): Symptomatic polycystic liver disease (PCLD) patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed Study NS-065/NCNP-01-201 through Week 25.~2. Willing and able to comply with scheduled visits, investigational product administration plan, and study procedures.~3. Stable dose of glucocorticoid (GC), and is expected to remain on the stable dose for the duration of the study.~Exclusion Criteria:~1. Serious or severe adverse event in Study NS-065/NCNP-01-201 that precludes safe use of NS-065/NCNP-01.~2. Patient had a treatment which was made for the purpose of dystrophin or its related protein induction after completion of Study NS-065/NCNP-01-201.~3. Patient took any other investigational drugs after completion of Study NS-065/NCNP-01-201.~4. Patient was judged by the investigator and/or the Sponsor that it was not appropriate to participate in the extension study for other reasons.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- NS-065/NCNP-01 40mg/kg (Type: EXPERIMENTAL): Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
- NS-065/NCNP-01 80mg/kg (Type: EXPERIMENTAL): Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must be affected by HCC~Patients must be 18 years old or older~Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.~Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~Subjects under the age of 18~Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C-arm CT + DSA as needed' (Type: EXPERIMENTAL): In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
- DSA only (Type: ACTIVE_COMPARATOR): In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to provide written informed consent or assent and to comply with study requirements~* Confirmation of PH1 disease~* Meet the 24 hour urine oxalate excretion requirements~* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days~Exclusion Criteria:~* Clinically significant health concerns (with the exception of PH1) or clinical evidence of extrarenal systemic oxalosis~* Clinically significant abnormal laboratory results~* Known active or evidence of HIV or hepatitis B or C infection~* An estimated GFR of \< 30 mL/min/1.73m\^2 at screening~* Received an investigational agent within 30 days or 5 half-lives before the first dose of study drug or are in follow-up of another clinical study~* History of kidney or liver transplant~* Known history of multiple drug allergies or allergic reaction to an oligonucleotide or GalNAc~* History of intolerance to subcutaneous injection~* Women who are pregnant, planning a pregnancy, or breast-feeding or those of child bearing potential and not willing to use contraception~* History of alcohol abuse within the last 12 months, or unable or unwilling to limit alcohol consumption throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/Lumasiran (Type: PLACEBO_COMPARATOR): Lumasiran-matching placebo (normal saline \[0.9% NaCl\]) was administered subcutaneously (SC) at Day 1 and Months 1, 2 and 3 during the 6-Month Double-blind (DB) Period, followed by lumasiran SC, 3.0 mg/kg, at Months 6, 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month Open-label Extension (OLE) period.
- Lumasiran/Lumasiran (Type: EXPERIMENTAL): Lumasiran was administered SC, 3.0 mg/kg, at Day 1 and Months 1, 2 and 3 during the 6-Month DB Period, followed by lumasiran SC, 3.0 mg/kg at Month 6, and lumasiran-matching placebo SC at Months 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month OLE period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Serologic evidence of HIV-1.~2. Plasma triglycerides \> 2.26 mmol/L (200 mg/dL) and/or Total Cholesterol \> 6 mmol/L (232 mg/dL) measured after a fasting period of at least 12 hours and confirmed by at least two measures separated by at least an interval of one week.~3. Body mass index between 25 and 30 kg/m2.~4. Absence NSAIDs, antihypertensive drugs, lipid-lowering drugs treatments or any other medication known to affect plasma lipid levels.~5. Alcohol intake \<20 g/day.~6. Absence of Diabetes mellitus and obesity (BMI \> 30)~7. Absence of heart and liver pathologies (within 3 months prior the study).~8. Absence of renal failure (serum creatinine \> 130 mmol/L) or Cr.Cl. \< 60 ml/min /1.73 m2.~Exclusion Criteria:~1. Pregnancy or absence of adequate contraception in childbearing age women.~2. Presence or fail to fulfil one or more of the conditions listed in paragraphs 2-8 of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHA (Type: EXPERIMENTAL): Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
- PLACEBO (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cryoanalgesia vs. Epidural in the Nuss Procedure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* scheduled for Nuss procedure for pectus excavatum correction~* at least 13 years old at the time of the procedure~Exclusion Criteria:~* age less than 13 years at time of procedure~* use of pain medication prior to procedure~* pectus carinatum, Poland's syndrome, or any chest wall anomaly other than pectus excavatum~* previous repair of pectus excavatum by any technique~* previous thoracic surgery~* congenital heart disease~* bleeding dyscrasia~* major anesthetic risk factors or history of previous problem with anesthesia~* pregnancy~* inability to communicate in English

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryoanalgesia (Type: EXPERIMENTAL): Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
- Thoracic Epidural (Type: ACTIVE_COMPARATOR): Thoracic epidural (ropivicaine, fentanyl).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Treatment of Alcohol Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers, 18-65 years of age~* Meets Diagnostic and Statistical Manual (DSM)-V criteria for current alcohol use disorder of moderate or greater severity, defined by DSM-V as ≥ 4 symptoms~* Abstinent a minimum of 3 days (but not more than 30 days) prior to randomization~* In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, ECG, urine test and lab tests~* Females with childbearing potential must have a negative serum pregnancy test on the screening visit and a negative urine pregnancy test at randomization and agree to use non-hormonal effective birth control for the study duration and one month thereafter~Exclusion Criteria:~* A medical condition or chronic use of a medication that contraindicates the administration of mifepristone~* Significant medical disorders or clinically significant findings on ECG (e.g., prolongation of the corrected QT interval,urine or blood tests that increase potential risk or interfere with study participation as determined by the Study Physician. Note: serum potassium below the normal range must be replaced to normal prior to randomization; individuals with serum potassium outside the range of normal will not be randomized~* Liver function tests more than 3 times the upper limit of normal or elevated bilirubin~* Female subjects with childbearing potential who are pregnant, nursing, or refuse to use effective non hormonal birth control for the 1-week of medication administration and one month thereafter~* Meets Diagnostic and Statistical Manual -V criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders other than alcohol or nicotine use disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: mifepristone 1200 mg daily (Type: ACTIVE_COMPARATOR): 1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
- Placebo daily, 1-week (Type: PLACEBO_COMPARATOR): Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete